The Joint Corp. Common Stock (JYNT)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn high returns on capital and sell at a sensible price. The Joint is a small franchisor and operator of cash-pay chiropractic clinics. It has moved from losses to profits: in FY2023, the period ended 2023-12-31, revenue was $47.0M and net income was -$9.8M; in FY2024, the period ended 2024-12-31, revenue was $52.2M with a -$5.8M loss; and in FY2025, the period ended 2025-12-31, revenue was $54.9M with net income of $2.9M, or diluted EPS of $0.19. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, had revenue of $15.2M and net income of $653,021, or $0.05 per diluted share. That is progress. But returns are still modest: FairStock calculations show ROCE of 2.33%, ROE of 10.62%, and a free cash flow yield of 4.3%. The balance sheet is conservative with D/E of 0.13, and Piotroski is 7/9, yet Altman Z is 1.78, near the caution zone. The moat is thin. Chiropractic adjustments are not proprietary; the cash-pay model avoids insurance friction but invites competition. At the 2026-10-13 close of $6.97, FairStock calculations put P/E at 49.82, P/B at 6.01, EV/EBITDA at 23.25, and the Graham Number at $1.88. Even allowing for the turnaround, the price embeds high expectations. I would want a larger margin of safety and evidence that recent profit is durable before calling this a bargain.

In plain English: The Joint runs and franchises chiropractic clinics that mostly charge customers directly rather than through insurance. The business has improved from losses to a small profit, but margins are thin and the improvement is still young. At the 2026-10-13 close of $6.97, the stock looks expensive compared with the company's earnings and accounting value, so it needs much better results to justify the price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K/A (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer